About 38 million Americans have diabetes, and more than 9 in 10 have type 2. Metformin is still common first, but treatment now centers on drugs that also protect the heart and kidneys: GLP-1 drugs such as semaglutide, dual GIP/GLP-1 tirzepatide, SGLT2 inhibitors, and finerenone for kidney disease. Research is racing toward stronger weight-and-sugar drugs (triple-hormone and amylin drugs), easier forms (GLP-1 pills, monthly shots, weekly insulin), and drugs that protect organs directly.
- 1,712studies open or running
- 136phase 3 trials
- 17,584papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
GLP-1 pills without food rulesHappened 1.91 point drop in HbA1c
Orforglipron lowered HbA1c by 1.91 points vs 1.47 with oral semaglutide over a year.
1.91: percentage-point drop in HbA1c with orforglipron 36 mg, vs 1.47 with semaglutide 14 mg.
Triple-hormone and amylin drugsHappened 15.3% weight loss
Retatrutide cut weight 15.3% and CagriSema 13.7% in type 2 diabetes, with large HbA1c drops.
15.3%: weight loss with retatrutide 12 mg, vs 2.6% with placebo.
Heart and kidney protectionHappened 24% fewer kidney events
Semaglutide cut major kidney events by 24%; tirzepatide matched dulaglutide for heart protection; starting finerenone and empagliflozin together cut kidney protein loss further.
24%: lower risk of major kidney events with semaglutide.
-
6 months
by May 2027
Retatrutide head to headLikely 15.3% weight loss vs placebo
Lilly's TRANSCEND-T2D-2 (1,250 people) compares retatrutide with semaglutide; its main analysis was due August 2026.
15.3%: weight loss with retatrutide 12 mg, vs 2.6% with placebo.
A once-monthly injectionLikely
Amgen's MARITIME-2 (1,105 people) tests monthly maridebart cafraglutide in type 2 diabetes with overweight; due January 2027.
-
12 months
by Nov 2027
Does semaglutide affect the eyes?Possible
Novo Nordisk's FOCUS (1,500 people) tests semaglutide's effect on diabetic eye disease over 5 years; due November 2027.
More GLP-1 optionsPossible
Viking's VANQUISH 2 (1,100 people, due July 2027) tests VK2735 in type 2 diabetes with obesity.
-
3 years
by late 2029
A wave of new pills and shotsPossible
AstraZeneca's elecoglipron pill (Eluminate trials), Novo's zenagamtide (AMBITION) and Roche's enicepatide (Enith) report in 2028.
Amylin drugs for diabetesPossible 13.7% weight loss (CagriSema)
Lilly's eloralintide (ENLIGHTEN-2, due January 2028) and higher-dose CagriSema (due February 2028) test amylin-based weight and sugar control.
13.7%: weight loss with CagriSema, vs 3.4% with placebo.
-
5 years
by late 2031
Blocking aldosterone to protect the heartPossible
Boehringer's EASi-PROTKT (11,800 people, due December 2029) tests vicadrostat with empagliflozin for heart outcomes in diabetes with high blood pressure.
Weekly insulin becomes routineLong shot 2 dose changes a year
With fixed-dose weekly insulins as effective as daily insulin, fewer injections and simpler dosing could become standard.
2: dose changes needed in a year, vs 8 with daily glargine (median).
The research paths
Stronger hormone drugs
15.3% weight lossDetails and 9 trialsHide
Drugs acting on two or three gut hormones (GLP-1, GIP, glucagon) or adding amylin, for bigger drops in blood sugar and weight.
WatchTRANSCEND-T2D-2; MARITIME-2; ENLIGHTEN-2.
- Retatrutide vs semaglutide (TRANSCEND-T2D-2)Eli Lilly · 1,250 people · fully enrolled Aug 2026
- Retatrutide with kidney impairment (TRANSCEND-T2D-3)Eli Lilly · 320 people · fully enrolled Oct 2026
- Monthly maridebart cafraglutide (MARITIME-2)Amgen · 1,105 people · fully enrolled Jan 2027
- Zenagamtide vs insulin glargine (AMBITION 7)Novo Nordisk · 1,778 people · enrolling Jul 2028
- Enicepatide (Enith1)Roche · 2,000 people · enrolling Jul 2028
- Higher-dose CagriSema vs semaglutideNovo Nordisk · 2,500 people · enrolling Feb 2028
- Eloralintide, an amylin drug (ENLIGHTEN-2)Eli Lilly · 1,035 people · enrolling Jan 2028
- Survodutide for blood sugarBoehringer Ingelheim · 600 people · enrolling Jan 2028
- NNC0487-0111 vs semaglutide (AMAZE 8)Novo Nordisk · 985 people · fully enrolled Dec 2028
Pills instead of shots
1.91 point drop in HbA1cDetails and 3 trialsHide
Small-molecule GLP-1 pills that are cheaper to make and need no fasting.
WatchEluminate trials.
Protecting heart, kidneys and eyes
24% fewer kidney eventsDetails and 2 trialsHide
Trials that measure heart attacks, kidney failure and eye disease, not just blood sugar.
WatchFOCUS; EASi-PROTKT.
Simpler insulin
2 dose changes a yearDetailsHide
Once-weekly basal insulins with fewer dose changes and less serious low blood sugar.
WatchApprovals and real-world use.
Borrowed from other conditions
From Hypertension and kidney disease
Vicadrostat
Phase 3
An aldosterone synthase inhibitor, the same class as baxdrostat for resistant high blood pressure.
From Kidney transplant rejection
Clazakizumab
Phase 2
An IL-6 antibody being tested to lower inflammation and heart risk in people with raised hsCRP.
Open to join now
-
Type 2 diabetes on metformin
Elecoglipron pill
Locations and eligibility → -
Type 2 diabetes
Zenagamtide
Locations and eligibility → -
Type 2 diabetes with obesity or overweight
Eloralintide
Locations and eligibility → -
Type 2 diabetes
Survodutide
Locations and eligibility → -
Type 2 diabetes with high blood pressure and heart disease
Vicadrostat plus empagliflozin
Locations and eligibility →
See every recruiting Type 2 diabetes trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Retatrutide lowers HbA1c and weight in early type 2 diabetes
TRANSCEND-T2D-1, The Lancet.
Orforglipron beats oral semaglutide on HbA1c
ACHIEVE-3, The Lancet.
Tirzepatide matches dulaglutide on heart outcomes
SURPASS-CVOT, NEJM.
Standard treatment today
- Newly diagnosedLifestyle changes and metformin; a GLP-1 drug or SGLT2 inhibitor early if heart, kidney or weight concerns.
- Heart disease or high heart riskA GLP-1 drug (or tirzepatide) and/or an SGLT2 inhibitor with proven heart benefit.
- Chronic kidney diseaseSGLT2 inhibitor, finerenone, and semaglutide, plus blood pressure control.
- ObesityTirzepatide or semaglutide at weight-loss doses; bariatric surgery for some.
- Needs insulinDaily basal insulin; weekly insulins are being introduced.
How to read this page, and sourcesHow to read this page, and sources
- Many new drugs are tested for both obesity and diabetes; results for people without diabetes are not shown here.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Type 2 diabetes trials recruiting now →